Share This Post

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

You are here:
You do not have access to this post.
1445534 {:YQSWFA7Q} 1 https://www.zotero.org/styles/urban-research-and-practice?source=1 50 default 1 1 149 http://www.hautkrebs-leitlinien.de/wp-content/plugins/zotpress/

Share This Post

Zur Werkzeugleiste springen